WO2022100736A1 - Composition pharmaceutique de glyburide administrée par voie nasale - Google Patents

Composition pharmaceutique de glyburide administrée par voie nasale Download PDF

Info

Publication number
WO2022100736A1
WO2022100736A1 PCT/CN2021/130720 CN2021130720W WO2022100736A1 WO 2022100736 A1 WO2022100736 A1 WO 2022100736A1 CN 2021130720 W CN2021130720 W CN 2021130720W WO 2022100736 A1 WO2022100736 A1 WO 2022100736A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
sodium
glyburide
parts
cyclodextrin
Prior art date
Application number
PCT/CN2021/130720
Other languages
English (en)
Chinese (zh)
Inventor
杨磊
杨少宁
林巧平
黄琦
翟慧
王鹏
任晋生
Original Assignee
江苏先声药业有限公司
海南先声药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏先声药业有限公司, 海南先声药业有限公司 filed Critical 江苏先声药业有限公司
Priority to CN202180076958.7A priority Critical patent/CN116648251A/zh
Publication of WO2022100736A1 publication Critical patent/WO2022100736A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention requires the prior patent application number 202011280101.0, which was submitted to the State Intellectual Property Office of China on November 16, 2020, and the name of the invention is "a pharmaceutical composition for nasal administration of glyburide and its preparation method" the priority of the application.
  • the entire contents of the aforementioned prior application are incorporated herein by reference.
  • the present invention relates to the field of pharmaceutical compositions, in particular, to a pharmaceutical composition for nasal administration of glyburide and a preparation method thereof.
  • Glyburide also known as excellent hypoglycemic, Daan therapy, Daanning, ethyl sulfonylurea, yuglukang, chlorosulfonyl cyclohexyl urea.
  • the chemical name is N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-5-chlorobenzamide, which is a sulfonic acid Urea hypoglycemic drugs, by inhibiting the ATP-sensitive potassium channel of pancreatic islet cells, depolarize the cell membrane and open the pressure-sensitive calcium ion channel, causing intracellular calcium ions to penetrate into islet cells and stimulate the release of insulin.
  • glyburide can promote the protection of cranial nerves.
  • Stroke commonly known as stroke, is an acute cerebrovascular disease. It is a group of diseases that damage the brain tissue due to the sudden rupture of blood vessels in the brain or the inability of blood to flow into the brain due to vascular obstruction. It is divided into ischemic stroke and hemorrhagic stroke. Among them, ischemic stroke accounts for more than 80% of strokes. According to the survey, stroke has become the first cause of death in my country and the leading cause of disability among Chinese adults. At the same time, stroke has the characteristics of high morbidity, high mortality and high disability rate, which seriously endangers human health and safety. Severe stroke can cause permanent neurological damage, and if not diagnosed and treated in time in the acute phase, serious complications and even death can result. The current drug treatment for stroke is mainly through thrombolysis, but it has a strict time limit.
  • Sur1-Trpm4 and Sur1-Kir6.2 (K ATP ) pathways are up-regulated in animal models such as stroke and cerebral contusion. Glyburide can inhibit these two pathways by targeting. It can protect and repair nerve cells in the brain and effectively reduce cerebral edema.
  • Biogen has completed the phase II clinical trial of glyburide in the treatment of stroke. It is administered by intravenous drip. The results show that it can effectively treat stroke, and the phase III clinical study of stroke is underway. and a phase II clinical study of cerebral contusion.
  • Glyburide has a strong hypoglycemic effect. In the process of treating stroke by intravenous injection, the increase of Glyburide in peripheral blood can easily cause serious adverse reactions of hypoglycemia.
  • the total dose and blood drug concentration are significantly smaller than the corresponding dose and concentration in diabetic patients; at the same time, due to the existence of the blood-brain barrier, the drug is difficult to Entering the brain through the blood-brain barrier, the drug concentration in the target organ is lower.
  • the above reasons all lead to the intravenous administration of glyburide far from reaching the optimal drug concentration for the treatment of stroke, and the long-term intravenous infusion of patients Compliance is also poor. Therefore, improving the brain targeting of glyburide and achieving an increase in the brain concentration of the drug without significantly increasing the blood concentration and the risk of hypoglycemia will have significant clinical value.
  • the volume of nasal administration is very small (the general administration volume of the human body is less than 200 microliters), while glyburide is weakly acidic and has poor solubility, especially in neutral and low pH conditions, the solubility is extremely low, and the solubility in water It is less than 5 ⁇ g/ml, and the pH of the preparation for nasal administration should not be too high, which greatly limits the use of glyburide.
  • the reported solution preparation of glyburide is only suitable for routine intravenous administration, and there is no Development of formulations that can be used for nasal administration.
  • the brain targeting of glyburide can be significantly improved by nasal administration, i.e., it can reach a higher level without increasing its adverse effect of hypoglycemia.
  • the brain concentration will have significant clinical value.
  • the present invention provides a pharmaceutical composition for nasal administration of glyburide and a preparation method thereof, which can achieve higher drug concentration in the brain without increasing the risk of hypoglycemia, that is, increase the risk of hypoglycemia.
  • Brain targeting will be particularly suitable for the treatment of diseases of the nervous system.
  • the present invention relates to a pharmaceutical composition for nasal administration of glyburide, which, in parts by weight, comprises 1-30 parts of glyburide, 10-1000 parts of an inclusion solubilizer, a solvent 1000 copies.
  • the weight ratio of the glibenclamide to the inclusion solubilizer is 1:6-1:200; preferably, the The weight ratio of glyburide to inclusion solubilizer is 1:10-1:200.
  • the content of glyburide in parts by weight, in the pharmaceutical composition, is 3-15 parts; preferably, the content of glyburide is 8-10 parts.
  • the inclusion solubilizer is selected from the group consisting of cyclodextrin, Tween, Span, polyoxyethylene castor oil, sodium lauryl sulfate, diethylene glycol monoethyl ether or a combination of more than one.
  • the inclusion solubilizer is cyclodextrin.
  • the cyclodextrin is selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and pharmaceutically acceptable cyclodextrin derivatives;
  • the acceptable cyclodextrin derivatives above are selected from the group consisting of dimethyl- ⁇ -cyclodextrin, 2-hydroxyethyl- ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin, 3-hydroxypropyl - a combination of one or more of beta-cyclodextrin, sulfobutyl ether-beta-cyclodextrin and trimethyl-beta-cyclodextrin.
  • the cyclodextrin is selected from ⁇ -cyclodextrin and its pharmaceutically acceptable cyclodextrin derivatives; preferably, the pharmaceutically acceptable cyclodextrin derivative is selected from A combination of one or more of 2-hydroxypropyl-beta-cyclodextrin, 3-hydroxypropyl-beta-cyclodextrin.
  • the content of the inclusion solubilizer in parts by weight, in the pharmaceutical composition, is 20-800 parts; preferably, the content of the inclusion solubilizer is 40-600 parts; further preferably, the content of the inclusion solubilizer is 40-600 parts.
  • the content of the co-solubilizer is 60-400 parts.
  • the pharmaceutical composition further includes a combination of one or more of a penetration enhancer, a stabilizer, a pH adjuster, and a bacteriostatic agent.
  • the penetration enhancer is selected from dodecyl- ⁇ -maltoside, sodium 8-(2-hydroxybenzamido)caprylate, sodium caprate, sodium caprylate, sodium cholate, deoxy One or more of cholic acid, taurodeoxycholic acid, ursodeoxycholic acid, sucrose monolaurate, EDTA, sodium lauryl sulfate, lauroylcarnitine, chitosan, palmitoylcarnitine combination of species.
  • the penetration enhancer is selected from dodecyl- ⁇ -maltoside, sodium caprate, sodium caprylate, ursodeoxycholic acid, bezoar deoxycholic acid, 8-(2-hydroxybenzene A combination of one or more of sodium carboxamido)caprylate.
  • the penetration enhancer is selected from a combination of one or more of dodecyl- ⁇ -maltoside, sodium caprate, and sodium caprylate.
  • the content of the penetration enhancer in parts by weight, in the pharmaceutical composition, is 0.1-10 parts; preferably, the content of the penetration enhancer is 1-8 parts; more Preferably, the content of the penetration enhancer is 2-5 parts.
  • the stabilizer is selected from the group consisting of povidone, gelatin, xanthan gum, acacia, tragacanth, dextran, sodium alginate, sodium carboxymethylcellulose, hypromellose , a combination of one or more of hydroxypropyl cellulose, methyl cellulose, carbomer, and polyvinyl alcohol.
  • the stabilizer is selected from a combination of one or more of povidone, gelatin, xanthan gum, sodium carboxymethylcellulose, hypromellose, and carbomer.
  • the stabilizer is selected from a combination of one or more of povidone, gelatin, xanthan gum, sodium carboxymethylcellulose, and hypromellose.
  • the content of the stabilizer in parts by weight, in the pharmaceutical composition, is 10-200 parts; preferably, the content of the stabilizer is 50-150 parts; more preferably , the content of the stabilizer is 80-100 parts.
  • the pH adjusting agent is selected from inorganic acids, inorganic bases, organic acids, organic bases and their buffer salt systems; preferably, the pH adjusting agent is selected from sodium hydroxide, hydrochloric acid, glycine, One or more combinations of hydrofluoric acid, triethylamine, acetic acid, phosphoric acid, malic acid, citric acid, acetate buffered salt, phosphate buffered salt and their aqueous solutions; A combination of one or more selected from sodium hydroxide, potassium hydroxide, hydrochloric acid, glacial acetic acid, sodium acetate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium carbonate, and sodium hydrogen carbonate.
  • the bacteriostatic agent is selected from the group consisting of methylparaben, propylparaben, sodium methylparaben, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, sangelamide, triclosan A combination of one or more of tert-butanol.
  • the bacteriostatic agent is selected from a combination of one or more of sodium methylparaben, sodium benzoate, sempermol, and chlorobutanol.
  • the content of the bacteriostatic agent in parts by weight, in the pharmaceutical composition, is 0.1-10 parts; preferably, the content of the bacteriostatic agent is 0.2-5 parts; more Preferably, the content of the bacteriostatic agent is 0.5-2 parts.
  • the solvent is water.
  • the pH of the pharmaceutical composition is 6.5-8.0.
  • the present invention also provides a preparation method of the pharmaceutical composition, comprising the following steps: weighing glyburide according to the recipe quantity, adding the inclusion solubilizer to the solvent, and using a pH adjuster to adjust the pH To 10-13, ultrasonic, adjusting the pH of the pharmaceutical composition with hydrochloric acid between 7.0-7.5, to prepare the pharmaceutical composition for nasal administration of glyburide.
  • the preparation method further includes the step of adding a combination of one or more of a penetration enhancer, a stabilizer, and a bacteriostatic agent.
  • the preparation method of the pharmaceutical composition comprises the following steps: weighing glyburide according to the recipe quantity, adding the inclusion solubilizer to the solvent, and adjusting the pH to 10-13 with a pH adjuster, Ultrasound, adding one or more combinations of penetration enhancers, stabilizers, and bacteriostatic agents, and adjusting the pH of the pharmaceutical composition with hydrochloric acid between 7.0 and 7.5 to prepare a nasal administration of glyburide.
  • pharmaceutical composition of the drug comprises the following steps: weighing glyburide according to the recipe quantity, adding the inclusion solubilizer to the solvent, and adjusting the pH to 10-13 with a pH adjuster, Ultrasound, adding one or more combinations of penetration enhancers, stabilizers, and bacteriostatic agents, and adjusting the pH of the pharmaceutical composition with hydrochloric acid between 7.0 and 7.5 to prepare a nasal administration of glyburide. pharmaceutical composition of the drug.
  • the preparation method of the pharmaceutical composition comprises the following steps: weighing glyburide according to the recipe quantity, adding the inclusion solubilizer to the solvent, and adjusting the pH to 10-13 with a pH adjuster, Ultrasound, adjust the pH of the pharmaceutical composition between 7.0-7.5 with hydrochloric acid, add one or more combinations of penetration enhancers, stabilizers, and bacteriostatic agents to prepare the nasal administration of glyburide pharmaceutical composition of the drug.
  • the pH adjuster adjusts the pH to 12-13.
  • the pH adjusting agent is selected from inorganic acids, inorganic bases, organic acids, organic bases and their buffer salt systems; preferably, the pH adjusting agent is selected from sodium hydroxide, hydrochloric acid, glycine, hydrofluoric acid , triethylamine, acetic acid, phosphoric acid, malic acid, citric acid, acetate buffered salt, phosphate buffered salt and the combination of one or more of their aqueous solutions; preferably, the pH regulator is selected from hydroxide A combination of one or more of sodium, potassium hydroxide, hydrochloric acid, glacial acetic acid, sodium acetate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium carbonate, and sodium hydrogen carbonate.
  • the pharmaceutical composition is a pharmaceutical composition for nasal administration.
  • the use of the pharmaceutical composition in the treatment of stroke and brain contusion in the treatment of stroke and brain contusion.
  • the intranasal administration of the pharmaceutical composition can achieve significantly higher levels in the brain than when administered intravenously, with a higher brain entry rate and cerebral blood ratio, without increasing Risk of hypoglycemia.
  • the pharmaceutical composition of the present invention can significantly improve the brain content of the drug, increase the brain entry rate and the cerebral blood ratio through nasal administration, achieve brain targeting without increasing the risk of hypoglycemia, and has significant clinical value.
  • the pharmaceutical composition of the present invention significantly improves the solubility of the drug, so that the composition is suitable for nasal administration;
  • the pharmaceutical composition of the present invention can significantly improve the intracerebral content of the drug, increase the brain entry rate and the cerebral blood ratio through nasal administration, and has a clear brain target It is tropic and does not increase the risk of hypoglycemia, which effectively avoids the technical problem of low drug concentration in the brain caused by the risk of hypoglycemia when intravenous injection is used in the treatment of stroke, brain contusion and other neurological diseases;
  • the nasal administration of the present invention has better compliance, does not damage the body barrier, and has better safety.
  • Figure 1 shows the plasma concentration-time curve of glyburide administered to rats by different administration methods.
  • Figure 2 shows the distribution-time curve of brain tissue after administration of glyburide to rats by different administration methods.
  • Glyburide and 2-hydroxypropyl- ⁇ -cyclodextrin were weighed according to the recipe and added to purified water. The pH was adjusted to 12.0 with 2 mol/L sodium hydroxide, and ultrasonicated for 15 minutes. The ⁇ -maltoside was dissolved, and the pH of the sample was adjusted between 7.0-7.5 with 1 mol/L hydrochloric acid to prepare the pharmaceutical composition of glyburide for nasal administration.
  • composition effect Dosage (mg) Glyburide main ingredient 8 2-Hydroxypropyl- ⁇ -cyclodextrin solubilization, inclusion 60 dodecyl-beta-maltoside osmotic 3 purified water solvent 1000
  • Glyburide and 2-hydroxypropyl- ⁇ -cyclodextrin were weighed according to the recipe and added to purified water. The pH was adjusted to 12.0 with 2 mol/L sodium hydroxide, ultrasonicated for 15 minutes, and the dodecyl of the recipe was added. - ⁇ -maltoside and PVPK30 are dissolved, and the pH of the sample is adjusted between 7.0-7.5 with 1 mol/L hydrochloric acid to prepare a pharmaceutical composition of glyburide for nasal administration.
  • composition effect Dosage (mg) Glyburide main ingredient 10 2-Hydroxypropyl- ⁇ -cyclodextrin solubilization, inclusion 100 dodecyl-beta-maltoside osmotic 3 PVPK30 Stablize 100 purified water solvent 1000
  • glyburide and 2-hydroxypropyl- ⁇ -cyclodextrin according to the recipe quantity and add them to purified water, adjust the pH to 13.0 with 2mol/L sodium hydroxide, ultrasonicate for 15min, add sodium caprate, The hypromellose is dissolved, the pH of the sample is adjusted between 7.0-7.5 with 1mol/L hydrochloric acid, and the prescription amount of sodium methylparaben is added to dissolve to prepare the pharmaceutical composition of glyburide for nasal administration .
  • composition effect Dosage (mg) Glyburide main ingredient 10 2-Hydroxypropyl- ⁇ -cyclodextrin solubilization, inclusion 100 Sodium caprate osmotic 3 Hypromellose Stablize 80
  • Glyburide and 2-hydroxypropyl- ⁇ -cyclodextrin were weighed according to the recipe and added to purified water. The pH was adjusted to 12.0 with 2 mol/L sodium hydroxide, ultrasonicated for 15 min, and the sample pH was adjusted to 7 with 1 mol/L hydrochloric acid. Between .0 and 7.5, the prescribed amount of sodium benzoate is added to dissolve, and the pharmaceutical composition of glyburide for nasal administration is prepared.
  • composition effect Dosage (mg) Glyburide main ingredient 3 2-Hydroxypropyl- ⁇ -cyclodextrin solubilization, inclusion 400 sodium benzoate Bacteriostatic 0.5 purified water solvent 1000
  • glyburide and 2-hydroxypropyl- ⁇ -cyclodextrin according to the recipe amount and add them to purified water, adjust the pH to 12.0 with 2mol/L sodium hydroxide, ultrasonicate for 15min, add the recipe amount of sodium caprylate to dissolve, The pH of the sample is adjusted between 7.0-7.5 with 1 mol/L hydrochloric acid, and the prescription amount of sodium benzoate is added to dissolve to prepare a pharmaceutical composition of glyburide for nasal administration.
  • composition effect Dosage (mg) Glyburide main ingredient 6 2-Hydroxypropyl- ⁇ -cyclodextrin solubilization, inclusion 200 sodium benzoate Bacteriostatic 0.5 Sodium Caprylate osmotic 2 purified water solvent 1000
  • composition effect Dosage (mg) Glyburide main ingredient 4 2-Hydroxypropyl- ⁇ -cyclodextrin solubilization, inclusion 60 purified water solvent 1000
  • glyburide injection Weigh 20 mg of glyburide, add dimethyl sulfoxide (DMSO) to 10 ml, prepare a 2 mg/ml stock solution, and then dilute to 0.02 mg/ml with normal saline.
  • DMSO dimethyl sulfoxide
  • Group B2 6 rats, in the awake state, instilled 10 ⁇ l of the pharmaceutical composition of Glyburide of Example 1 into the left and right nasal cavity, took the brain tissue at 0.25h and 1h after administration, and measured the blood sugar at 0.25h at the same time ; The blood vessels were removed from the brain tissue, the water was sucked dry, and the homogenized treatment was carried out, and the concentration of glyburide in the brain tissue was determined by LC-MS method (Table 8).
  • Group C2, 18 rats were instilled 10 ⁇ l of the pharmaceutical composition of Glyburide of Example 2 into each of the left and right nasal cavities in a conscious state; Group A2, 18 rats, were injected with Glyburide of Comparative Example 2 through the tail vein Benurea injection, the dose is 0.1mg/kg, blood glucose and jugular venous plexus blood were measured before administration, and jugular venous plexus blood was collected and measured 0.25h, 1h, 2h, 4h, 8h, 24h after administration. Blood sugar and brain tissue.
  • the concentration of glyburide in plasma and brain tissue was determined by LC/MS method (Table 8, Figure 2), and the cerebral blood ratio was calculated (Table 9).
  • BQL is 0.15ng/g below the lower limit of quantification.
  • the concentration of the pharmaceutical composition of glyburide in the brain tissue at each time point after nasal administration was significantly increased to 4-10. times (Table 8, Figure 2), and the cerebral-to-blood ratio at each time point increased to 2-fold or more (Table 9), indicating that there is a direct nasal-brain transport pathway for glyburide, with obvious brain targeting.
  • the blood drug concentration was associated with the occurrence of hypoglycemia.
  • the Cmax of nasal administration in group B1 was lower than that in intravenous administration group
  • the Cmax of nasal administration of group C1 was slightly higher than that of intravenous administration group
  • the lowest blood glucose values of B2 and C2 groups were higher than the lowest blood glucose value of intravenous administration group, indicating that the medicine of glyburide of the present invention
  • the risk of hypoglycemia after nasal administration of the composition was not higher than in the intravenous administration group.
  • the pharmaceutical composition for nasal administration of glyburide of the present invention can significantly increase the amount of the drug entering the brain, increase the rate of entering the brain and the cerebral blood ratio, improve the brain targeting, and at the same time It is expected to have significant clinical application value without increasing the side effects of hypoglycemia caused by glyburide in peripheral blood.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique de glyburide administrée par voie nasale et son procédé de préparation. La composition pharmaceutique résout les problèmes techniques de faible concentration de médicament dans le cerveau et de risque élevé d'hypoglycémie sévère comme effet secondaire, et améliore significativement la solubilité de médicaments, ce qui permet d'obtenir une concentration plus élevée dans le cerveau sans augmenter le risque d'hypoglycémie, d'améliorer la capacité de ciblage du cerveau, et d'avoir une meilleure observance.
PCT/CN2021/130720 2020-11-16 2021-11-15 Composition pharmaceutique de glyburide administrée par voie nasale WO2022100736A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180076958.7A CN116648251A (zh) 2020-11-16 2021-11-15 一种格列本脲的经鼻给药的药物组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011280101 2020-11-16
CN202011280101.0 2020-11-16

Publications (1)

Publication Number Publication Date
WO2022100736A1 true WO2022100736A1 (fr) 2022-05-19

Family

ID=81600790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/130720 WO2022100736A1 (fr) 2020-11-16 2021-11-15 Composition pharmaceutique de glyburide administrée par voie nasale

Country Status (2)

Country Link
CN (1) CN116648251A (fr)
WO (1) WO2022100736A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DU YUELIAN, GAO XIAOFENG: "Research progress of nasal drug delivery system", SHANXI MEDICAL JOURNAL, vol. 33, no. 1, 30 January 2004 (2004-01-30), pages 50 - 52, XP055931036 *
ESCLUSA-DIAZ, M.T. ; TORRES-LABANDEIRA, J.J. ; KATA, M. ; VILA-JATO, J.L.: "Inclusion complexation of glibenclamide with 2-hydroxypropyl-@b-cyclodextrin in solution and in solid state", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 1, no. 6, 1 June 1994 (1994-06-01), NL , pages 291 - 296, XP025487246, ISSN: 0928-0987, DOI: 10.1016/0928-0987(94)90037-X *
LI XIAO, ZHANG YI-MIN: "Preparation and Characterization of Hydroxypropyl-β-cyclodextrin/Glibenclamide Inclusion Complex", JOURNAL OF QINGDAO UNIVERSITY OF SCIENCE AND TECHNOLOGY (NATURAL SCIENCE EDITION), QINGDAO-KEJI-DAXUE, CN, vol. 30, no. 2, 15 April 2009 (2009-04-15), CN , pages 118 - 122, XP055931067, ISSN: 1672-6987 *
LIU KAI, HE YUAN: "Preparation of butyl ether-β-cyclodextrin and glibenclamide clathrate", JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 34, no. 7, 15 July 2015 (2015-07-15), pages 401 - 403, XP055931048, ISSN: 2095-5375, DOI: 10.13506/j.cnki.jpr.2015.07.011 *
LUCIO DAVID; IRACHE JUAN MANUEL; FONT MARIA; MARTINEZ-OHARRIZ MARIA CRISTINA: "Supramolecular structure of glibenclamide and β-cyclodextrins complexes", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 530, no. 1, 2 August 2017 (2017-08-02), NL , pages 377 - 386, XP085169231, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2017.08.002 *
WANG, JU: "Effect of Intranasal Administration of Glibenclamide on the Treatment of Traumatic Brain Injury in Mice", SHANGHAI JIAOTONG DAXUE XUEBAO (YIXUE BAN) [SHANGHAI JIAOTONG UNIVERSITY. JOURNAL (MEDICAL SCIENCE)], SHANGHAI JIAOTONG DAXUE, CN, vol. 40, no. 2, 2 February 2020 (2020-02-02), CN , pages 157 - 162, XP055930584, ISSN: 1674-8115, DOI: 10.3969/j.issn.1674-8115.2020.02.003 *

Also Published As

Publication number Publication date
CN116648251A (zh) 2023-08-25

Similar Documents

Publication Publication Date Title
JP5656692B2 (ja) アミオダロンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
JP3421348B2 (ja) 安定なブデゾナイド溶液、その製造方法並びに該溶液を浣腸剤及び医薬泡沫剤として使用する用途
JP3683595B2 (ja) セチリジン含有抗アレルギー点眼点鼻用組成物
EP2789349B1 (fr) Préparation liquide comprenant du pimobendane
US5376632A (en) Cyclodextrin based erythropoietin formulation
JP6542193B2 (ja) 後眼部へ薬物を送達するための眼用製剤
CA2495864A1 (fr) Formulation de complexe d'aripiprazole et methode associee
EP1759702B1 (fr) Procédé de préparation d'une solution ophtalmique de latanoprost et solution ainsi obtenue
KR20140009332A (ko) 고농도 올로파타딘 안과용 조성물
JPH05213757A (ja) 水性液剤
EP0709099A2 (fr) Suspension aqueuse nasale comprenant cyclodextrine
US20100267817A1 (en) Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
NO327444B1 (no) Farmasøytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa
US8034371B2 (en) Intranasal compositions
WO2022100736A1 (fr) Composition pharmaceutique de glyburide administrée par voie nasale
EP3556349B1 (fr) Préparation liquide parentérale comprenant un composé carbamate
US5977180A (en) Anandamide analog compositions and method of treating intraocular hypertension using same
WO2022100737A1 (fr) Composition pharmaceutique pour administration nasale de glyburide et sa méthode de préparation
JPH08151332A (ja) 点鼻用水性懸濁液
WO2023030430A1 (fr) Formulation ophtalmique pour la prévention et/ou le traitement de la cataracte par administration de gouttes oculaires
MX2009002280A (es) Formulacion acuosa que comprende un agente antitumoral.
CN116919888A (zh) 一种用于经鼻给药的格列本脲的药物组合物及其制备方法
WO2022105720A1 (fr) Composition pharmaceutique de glibenclamide et son procédé de préparation
WO2022007743A1 (fr) Forme posologique pour administration par les muqueuses et son utilisation
WO1995025518A1 (fr) Solution aqueuse de levocabastine a usage ophtalmique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21891256

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202180076958.7

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21891256

Country of ref document: EP

Kind code of ref document: A1